A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy

European Journal of Cancer

Volumn 33, Issue 14, 1997, Pages 2418-2427

  McSheehy, P M J ^a,b   Seymour, M T ^c   Ojugo, A S E ^a,b   Rodrigues, L M ^a   Leach, M O ^b   Judson, I R ^b   Griffiths, J R ^a  

^a Dept Cell Molec Sci St G ^*  (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

5 Fluorouracil; Human tumours; Interferon ; Pharmacokinetics; Phosphorus fluorine magnetic resonance spectroscopy

Indexed keywords

FLUOROURACIL;

ARTICLE; CANCER; CANCER CHEMOTHERAPY; HUMAN; HUMAN CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PH MEASUREMENT; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; FLUOROURACIL; HT29 CELLS; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS, EXPERIMENTAL; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; THYMIDINE;

EID: 0031424746     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00336-5     Document Type: Article

References (44)

1. Sotos GA, Grogan L, Allegra C. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev. 20:1994;11-49.
2. Aschele C, Sobrero A, Faderan MA, Bertino JR. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer HCT-8 sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 52:1992;1855-1864.
3. Naguib FNM, el Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res. 45:1985;5405-5412.
4. Rustum YM, Harstrick A, Cao S, et al. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 1997, 15, 389-400.
5. 19F-NMR. Br J Cancer. 50:1984;113-117.
6. 19F NMR spectroscopy. NMR Biomed. 4:1991;274-278.
7. 19F Magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine RIF-1 tumours and liver. Cancer Res. 51:1991;1384-1390.
8. 19F magnetic resonance spectroscopy. Magn Reson Imaging. 10:1992;385-392.
9. McSheehy PMJ, Prior MJW, Griffiths JR. Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo. Br J Cancer. 60:1989;303-309.
10. 19F-MRS study in vivo. Br J Cancer. 65:1992;369-375.
11. 19F NMR spectroscopy. Magn Reson Med 1991, 19, 113-123.
12. 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. Ann Oncol 1993, 4, 597-602.
13. 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J Clin Oncol 1990, 8, 1868-1873.
14. Presant CA, Wolf W, Waluch C, et al. Association of intratumoral pharmacokinetics of 5-fluorouracil with clinical response. The Lancet 1994, 343, 1184-1185.
15. Grem JL. Fluorinated Pyrimidines. In Chabner BA, Collins JM, eds. Cancer Chemotherapy: Principles & Practice. Philadelphia, JB Lippincott Company, 1990, 180-224.
16. 19F nuclear magnetic resonance spectroscopy. Cancer Res. 51:1991;5770-5773.
17. 31P magnetic resonance spectroscopy in murine tumours. Br J Cancer. 72:1995;905-911.
18. 31P NMR. Proc Natl Acad Sci USA. 80:1983;2748-2751.
19. Johnson A, Woolard RC. STRIPE: an interactive computer programme for the analysis of drug pharmacokinetics. J Pharmacol Methods. 9:1982;193-199.
20. Stubbs M, Rodrigues LM, Howe FA, et al. Metabolic consequences of a reversed pH gradient in rat tumours. Cancer Res 1994, 54, 4011-4016.
21. Findlay MPN, Leach MO. In vivo monitoring of fluoropyrimidine metabolites: magnetic resonance spectroscopy in the evaluation of 5-fluorouracil. Anticancer Res. 5:1994;260-280.
22. 19F-MRS studies of fluoropyrimidine chemotherapy. A review. NMR Biomed. 2:1989;133-141.
23. Milano G, Etienne M-C. Dihydropyrimidine dehydrogenase and clinical pharmacology of 5-fluorouracil (review). Anticancer Res. 14:1994;2295-2298.
24. 19F NMR spectroscopic observation of 5-fluorouracil metabolism in the isolated perfused mouse liver model. NMR Biomed. 1:1988;113-120.
25. 19F nuclear magnetic resonance spectroscopy study in vivo. Cancer Chemother Pharmacol. 37:1996;259-265.
26. Greenhalgh DA, Parish JH. Effect of 5-fluorouracil combination therapy on RNA processing in human colon carcinoma cells. Br J Cancer. 61:1990;415-419.
27. Elias I, Sandoval JM. Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun. 163:1989;867-874.
28. Schwartz EL, Hoffman M, O'Connor CJ, Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells. Biochem Biophys Res Commun. 182:1992;1232-1239.
29. Chu E, Zinn S, Boarman D, Allegra CJ. Interaction of interferon-γ and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res. 50:1990;5834-5840.
30. Seymour MT, McSheehy PMJ, Dobson N, Rodrigues LM, Clemens M, Slevin M. 5-Fluorouracil and interferon-α: interactions in vivo and in vitro. Br J Cancer 1992, 65 (Suppl. XVI), 17.
31. Houghton JA, Cheshire PJ, Morton CL, Stewart CF. Potentiation of 5-fluorouracil-Leucovorin activity by α2a-interferon in colon adenocarcinoma xenografts. Clin Cancer Res. 1:1995;33-40.
32. Yee LK, Allegra CJ, Steinberg SM, Grem JL. Decreased catabolism of 5-fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon-α-2a. J Natl Cancer Inst. 84:1992;1820-1825.
33. 19F spectroscopy in patients on a protracted venous infusion with and without interferon-α Ann Oncol. 7:1996;47-53.
34. Hoffman MA, Wadler S. Mechanisms by which interferon potentiates chemotherapy. Clinical Sci Rev. 11:1993;310-313.
35. Seymour MT, Patel N, Johnston A, Joel SP, Slevin ML. Lack of effect of interferon-α2a upon 5-fluorouracil pharmacokinetics. Br J Cancer. 70:1994;724-728.
36. Griffiths JR. Are cancer cells acidic? Br J Cancer. 64:1991;425-427.
37. Gerweck LE, Rhee JG, Koutcher JA, Song CW, Urano M. Regulation of pH in murine tumour and muscle. Radiat Res. 126:1991;206-209.
38. Ojugo ASE, McSheehy PMJ, Stubbs M, et al. Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells. Br J Cancer, in press.
39. Maheshwari RK, Sidhu GS, Bhartiya D, Friedman RM. Primary amines enhance the antiviral activity of interferon against a membrane virus: role of intracellular pH. J Gen Virol. 72:1991;2143-2152.
40. Ladoux A, Damais C, Krawice I, Abita J-P, Frelin C. An increase in intracellular pH is a general response of promonocytic cells to differentiating agents. FEBS Lett. 234:1988;353-356.
41. + exchange-dependent and -independent cytoplasmic alkalinisation. J Biol Chem. 263:1988;7359-7363.
42. 31P-Nuclear magnetic resonance analysis of interferon-induced alterations of phospholipid metabolites in interferon-sensitive and interferon-resistant Friend leukaemia cell tumours in mice. Cancer Res. 46:1986;2849-2857.
43. + exchanger. J Membrane Biol. 90:1986;1-12.
44. Peters GJ, Lankelma J, Kok RM, et al. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumours as compared with plasma. Cancer Chemother Pharmacol 1993, 31, 269-276.